Amylin Analog
AbbVie Enters Obesity Market with $2.3 Billion Gubra Deal for Amylin Analog
AbbVie, Gubra, Obesity treatment, GUB014295 (GUBamy), Amylin analog, Weight loss drug, Pharmaceutical licensing deal
Actionable Insights Powered by AI
AbbVie, Gubra, Obesity treatment, GUB014295 (GUBamy), Amylin analog, Weight loss drug, Pharmaceutical licensing deal